Outcomes of the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP)

Contents

Overview

This is a record of treatments considered and recommended by the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) for national publicly funded trials.

UK-CTAP is part of the Clinical Trials Infrastructure National Core Study formed to accelerate delivery of large scale trials for COVID-19 treatments.

The role of UK-CTAP is to consider potential COVID-19 treatments proposed through the open nominations portal.

The portal and proposal process is managed by a UK Research and Innovation (UKRI) team composed of scientists and programme staff. Professor Patrick Chinnery, MRC clinical director, is the chair of UK-CTAP.

The panel reviews available scientific evidence and makes recommendations to the principal investigators of each trial and Professor Chris Whitty, the Chief Medical Officer for England (CMO England) and Chief Scientific Adviser for the Department of Health and Social Care (DHSC).

The national platform clinical trials are:

  • RECOVERY+
  • REMAP-CAP
  • PRINCIPLE
  • AGILE
  • HEAL-COVID.

UK-CTAP has ceased its operations as of September 2021. See some of the highlights of what UK-CTAP achieved in the last 15 months (PDF, 254KB).

Last updated: 25 October 2021

NOTE Council web content is being transitioned to this website – let us know if you have feedback or would like to help us test new developments.